Form 4: Nektar Director R. Scott Greer Receives Stock Options

Nektar Therapeutics director R. Scott Greer was granted 8,000 stock options with an exercise price of $56.90, which will vest over a one-year period starting September 30, 2025.

Summary

• R. Scott Greer, a Director of Nektar Therapeutics, was granted 8,000 stock options.
• The options have an exercise price of $56.90 per share.
• The grant date for these options was September 30, 2025.
• The options will vest in substantially equal monthly installments over a one-year period, commencing on September 30, 2025.
• The expiration date for these stock options is September 29, 2033.
• The derivative securities were acquired at a price of $0.00.
• Following this transaction, R. Scott Greer beneficially owns 8,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (stock option grant) which is generally seen as a neutral to slightly positive event as it aligns director interests with shareholders, but does not contain significant news to dramatically shift sentiment.

Positives

• The granting of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• The options have a long expiration date (September 29, 2033), providing ample time for potential value realization.

Negatives

• No specific negative information is contained within this routine Form 4 filing.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

The 8,000 stock options granted to Director R. Scott Greer will vest in substantially equal monthly installments over a one-year period, beginning on September 30, 2025, indicating a future incentive structure.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, serving as a form of equity compensation to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• Equity compensation, particularly through stock options, is a standard component of director remuneration across publicly traded companies, including those in the biotech sector.
• While specific grant sizes and exercise prices vary based on company size, performance, and individual roles, the structure of vesting over time is typical to encourage sustained commitment.
• No specific comparable companies, projects, or results are mentioned in the filing to allow for a detailed comparison.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's interests with shareholders, potentially leading to better long-term performance. However, it also represents potential future dilution if options are exercised.
• Employees: No direct impact on employees is mentioned.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned.

Next Steps

• The stock options will begin vesting in substantially equal monthly installments over the one-year period starting September 30, 2025.

Key Dates

Keywords

Nektar Therapeutics, NKTR, R. Scott Greer, stock options, director compensation, insider transaction, equity grant, vesting schedule